XARELTO is associated with fewer hospitalization days and outpatient visits compared to warfarin in patients with non-valvular atrial fibrillation, according to data presented at the American Heart Association 2014 Scientific Sessions.
When examining the cost of anticoagulant treatment, the cost between the medications become comparable due to the cost savings from reduced hospital length of stay with XARELTO, said Concetta Crivera, PharmD, M.P.H., Director, HECOR Cardiovascular, Janssen Scientific Affairs LLC.
Researchers looked at more than 4,500 patients in the Humana integrated claims database between May 2011 and December 2012. The mean all-cause and NVAF-related total of hospitalization days were fewer for XARELTO® compared to warfarin (2.71 vs. 3.87 days; 2.11 vs. 3.02 days).
